Wound-Adhering Sustained-Release Pharmaceutical Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a sustained release pharmaceutical formulation that can be easily applied to tooth extraction sockets without preparation, adheres to the wound, resists erosion, and provides pain management during the healing process while promoting wound healing, without adverse interactions with blood or tissue toxicity, and is biocompatible.
Innovation Solution
A pharmaceutical formulation comprising an active ingredient dispersed in a water-miscible and hygroscopic network-forming material, optionally with a hydrophobic component and a reinforcing member, which forms a cohesive matrix that adheres to the wound and provides controlled release of analgesics or anesthetics for pain management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a sustained release pharmaceutical formulation is designed to maintain constant drug level for specific period, then drug delivery duration is improved, but formulation complexity increases
Solution Approach 1:
The patent utilizes hydrophobic components with specific log P values (0.5-5.0) and molecular weights (500-10,000 Da) to control drug release parameters. By adjusting these physical-chemical parameters of the hydrophobic material, the formulation achieves sustained release over extended periods without requiring complex multi-component systems or sophisticated delivery mechanisms.
Solution Approach 2:
The formulation combines hydrophobic components with pharmaceutical excipients and active ingredients to create a composite material system. This composite approach allows the hydrophobic material to serve dual purposes: as a vehicle for drug delivery and as a matrix that provides sustained release characteristics, thereby reducing overall formulation complexity while extending duration of action.
2Reliability
If the formulation is designed to adhere to the wound and resist erosion, then reliability is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies hydrophobic components with controlled log P values (0.5-5.0) and molecular weights (500-10,000 Da) that inherently provide adhesion and erosion resistance. These parameter specifications allow the formulation to achieve reliable wound adhesion through the natural properties of the hydrophobic material rather than requiring precise manufacturing controls for adhesion promotion.
Solution Approach 2:
The formulation employs biodegradable hydrophobic components that are designed to be absorbed and metabolized by the body. This approach prioritizes biocompatibility and eliminates the need for permanent, highly precise manufacturing structures, as the material naturally degrades over time without requiring complex manufacturing precision to maintain structural integrity.
3Object-affected harmful factors
If the formulation is designed to be biocompatible and hemostatic, then safety is improved, but device complexity increases
Solution Approach 1:
The hydrophobic components are selected to be inherently biocompatible and hemostatic, utilizing their natural properties to interact favorably with blood and tissue. The formulation leverages the self-service capability of the hydrophobic material to provide hemostasis and biocompatibility without requiring additional active ingredients or complex mechanisms, thereby maintaining simplicity while ensuring safety.
Solution Approach 2:
The formulation utilizes the hydrophobicity of the components, which could potentially be considered a harmful property for water-based biological systems, and converts it into a benefit by selecting hydrophobic materials with appropriate log P values that enhance membrane permeability and biocompatibility. This approach transforms a potential adverse property into a beneficial characteristic for sustained release and tissue interaction.
4Ease of operation
If the formulation requires minimal preparation by clinician, then ease of operation is improved, but formulation complexity may increase
Solution Approach 1:
The formulation is designed as a pre-prepared composition with all necessary components (hydrophobic materials, excipients, and active ingredients) already combined in the correct proportions. This preliminary action during manufacturing eliminates the need for clinician preparation steps such as mixing, dosing, or configuration, thereby maximizing ease of operation while keeping the formulation complexity managed through standardized manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively manages acute and sub-acute pain by maintaining drug delivery over time, adhering to the wound, and promoting healing, while being biocompatible and resistant to erosion.
Implementation Method 1
water-miscible and hygroscopic network-forming material
Implementation Method 2
adheres to the wound
Implementation Method 3
controlled release of analgesics or anesthetics for pain management
Implementation Method 4
sustained release pharmaceutical formulation
Implementation Method 5
active ingredient dispersed in a water-miscible and hygroscopic network-forming material, optionally with a hydrophobic component
Data Source
AI summary
A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.